A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321 - Wikidata - wikimedia - TriplyDB

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321

http://www.wikidata.org/entity/Q35058595

about

Combination therapeutics in complex diseases Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Effects of carbon ion irradiation and X-ray irradiation on the ubiquitylated protein accumulation.Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.Proteasome-associated deubiquitinases and cancer.Positioning of proteasome inhibitors in therapy of solid malignancies.Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.

P2860

Q28076891-DE4EF6DA-40FE-4BCD-95AC-A9E95DBF056E Q33841579-6064B4EC-8956-40EC-B05C-684C2A95D196 Q36368864-A6148D22-B7BD-47CB-9110-56009D609CF9 Q36992155-2A8F292F-6500-4245-ADF9-6D37B9822ECF Q38809124-0F90BA1F-B4A9-4C8D-9500-991828841F86 Q41291592-FE73365B-8D73-476A-9D01-B73280D1D4D8 Q47161331-678619D0-E283-4A45-8BFB-FDC33B53A2B2 Q47353792-0F4CE971-B3A2-495E-9C4F-9BABBCCC8713 Q52538370-3363722B-171B-4FB4-AD46-F20C8297497C

P2860

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321

http://www.wikidata.org/entity/Q35058595

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@ast

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@en

type

label

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@ast

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@en

prefLabel

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@ast

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@en

P1433

Q35058595-EC3DC49D-6966-4615-B53E-1A1A49354BC7

P1476

Q35058595-CE2E08BE-451D-45F2-872A-795A123CF36B

P2093

Q35058595-087D26D9-D28E-485A-9716-F33F41C1951F

Q35058595-114B6378-F2FA-4F80-94BA-71DD292A6D62

Q35058595-118418ED-1775-4399-9EF2-3E81B15621A9

Q35058595-262299B4-2232-436A-B0BE-4199A34F38BA

Q35058595-26A3A648-AD42-4CD9-AE6F-CF681DC72982

Q35058595-4BD3EDB7-EAF3-4CB4-84C0-99C9B418CB96

Q35058595-653181BC-127E-483A-8BD2-A83EE4D483BE

Q35058595-68DE0656-3702-42D2-AB4B-EA67771D742C

Q35058595-8023A82D-F2E6-42FA-8257-014118D18685

Q35058595-A1BCA7BE-3C26-41BC-92CE-AEA5CB3803FF

P2860

Q35058595-0D8BC612-3087-43C7-9968-B7755D9477CE

Q35058595-141492A8-3517-4C6A-B4DD-6D328961CC74

Q35058595-18F59007-F3BB-4D71-8DE7-2726A63CD04F

Q35058595-19A54B1E-36E5-4BCD-BE7C-C0DA8DF7F320

Q35058595-1CBE181F-5290-4675-B1D1-78FABCCB8609

Q35058595-20F1ED8B-D95F-4476-B51B-89165A6A81BD

Q35058595-27AE4361-73AC-443F-8BE1-221E3B977765

Q35058595-306E61FD-8CB0-4260-B9C8-25354FDBDC2E

Q35058595-509931B7-AC8E-47B9-8473-E13AECA5FFC1

Q35058595-53B4D7DB-EBF3-4B36-9A70-364F6A286C99

P304

Q35058595-021EDFB5-5337-4A95-8724-5A289DD8F0DD

P31

Q35058595-DF8EE72E-F089-4B36-B424-24BABF806126

P356

Q35058595-27976119-6CC6-4834-A73A-89F535132B12

P433

Q35058595-7EF21699-C76C-4EEF-81AF-04D33FA4934C

P478

Q35058595-C184B9B4-67CC-4B16-9FBC-8B7BE2816422

P577

Q35058595-5C726FF2-B090-4BE6-ADD6-2CFDCCA86A53

P698

Q35058595-67F522EB-DFF5-43E9-B395-9ABBD3229308

P921

Q35058595-6E41AEDC-A2FB-48B2-81DB-E89A7AA146D4

P932

Q35058595-A4F12C0A-2A26-4EC2-9573-CB5B0D62AAB0

P356

JTO.0000000000000383

P1433

Journal of Thoracic Oncology

P1476

A phase I/II study of bortezom ...... Treatment Group (NCCTG)-N0321

@en

P2093

Alex A Adjei

http://www.w3.org/2001/XMLSchema#string

Bassam I Mattar

http://www.w3.org/2001/XMLSchema#string

David B Johnson

http://www.w3.org/2001/XMLSchema#string

Donald W Northfelt

http://www.w3.org/2001/XMLSchema#string

James D Bearden

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Meyers

http://www.w3.org/2001/XMLSchema#string

Julian R Molina

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

Marie-Christine Aubry

http://www.w3.org/2001/XMLSchema#string

Nathan R Foster

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer.

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

P304

172-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000383

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25247339

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4320011

http://www.w3.org/2001/XMLSchema#string